Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Jacqueline Garcia, MD
- Target Recruit Count
- 100
- Registration Number
- NCT03613532
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelofibrosisRecurrent Hodgkin LymphomaTherapy-Related Acute Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid System NeoplasmAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Non-Hodgkin Lymphoma
- Interventions
- Biological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: CyclophosphamideDrug: CyclosporineDrug: Fludarabine PhosphateDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03602898
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT03602131
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03600909
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT03597594
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 48
- Registration Number
- NCT03579875
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Autologous Gene Therapy for Artemis-Deficient SCID
- Conditions
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 25
- Registration Number
- NCT03538899
- Locations
- 🇺🇸
University of California, San Francisco (UCSF) Children's Hospital, San Francisco, California, United States
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03515707
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 120
- Registration Number
- NCT03384212
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 120
- Registration Number
- NCT03384225
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.